Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.47 |
| ▸ | HTR2C | P28335 | 8/20 | 0.47 |
| ▸ | HTR2B | P41595 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27002000 | 0.86 | HTR2A (0.48) | HTR2AHTR2CHTR2BMAPTTAAR1 | |
| SCHEMBL29279562 | 0.82 | MAPT (0.39) | MAPTCYP1A2 | |
| SCHEMBL27002165 | 0.81 | KMT2A (0.45) | HTR2AHTR2CMAPT | |
| SCHEMBL29279518 | 0.78 | MAPT (0.36) | MAPT | |
| SCHEMBL20970965 | 0.77 | HTR2A (0.55) | HTR2AHTR2CHTR2BMAPTTAAR1 | |
| SCHEMBL26065169 | 0.77 | CYP1A2 (0.46) | HTR2AHTR2CHTR2BTAAR1CYP1A2 | |
| SCHEMBL26065189 | 0.77 | TAAR1 (0.47) | HTR2AHTR2CHTR2BMAPTTAAR1 | |
| SCHEMBL29814900 | 0.76 | KMT2A (0.43) | MAPT | |
| SCHEMBL14655707 | 0.75 | HTR2A (0.79) | HTR2AHTR2CHTR2BMAPT | |
| SCHEMBL29528780 | 0.75 | HTR2A (0.79) | HTR2AHTR2CHTR2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| CN-117642379-A | Phenylalkylamines and methods of making and using the same | 吉尔伽美什制药公司 | 2024-03-01 | — | — | CN | disclosed |
| EP-4305019-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | Gilgamesh Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2022192781-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166618-A1 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | PNMT, HTR6, HTR2C | HTR2A 11/4885HTR2C 3/4885HTR2B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.